Dr. Arijit Nag

About

Correspondance:
Department of Clinical Hematology and BMT,
TATA Medical Center,
14, Main Arterial Road (E-W),
DH Block, New town, Kolkata: 700160.

e-mail: [email protected] , [email protected]

Current Position:
Consultant,
Clinical Hematology and BMT, TATA Medical Center.

Areas of interest:
- Acute Leukemia (with focus on Acute Lymphoblastic Leukemia)
- Stem cell transplantation (with focus on transplants in Thalassemia and Aplastic Anemia)
- Cancer associated Thrombosis.

Employment

• Tata Medical Center Consultant
  2020 - Present
• Princess Margaret Cancer Centre Clinical Fellow, Messner Allogeneic BMT Program
  2019 - 2020

Education

• University of Texas MD Anderson Cancer Center Clinical Preceptorsjip
  2017 - 2017
• Institute of Hematology and Transfusion Medicine, Medical College and Hospital, Kolkata DM (Clinical Hematology)
  2014 - 2017
• Royal College of Physicians MRCP
  2011 - Present
• Institute of Post Graduate Medical Education And Research MD (Internal Medicine)
  2011 - 2014
• Nil Ratan Sircar Medical College and Hospital MBBS
  2004 - 2010

Projects & Funding

Projects & funding information is unavailable.

Publications (46)

• Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukaemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1/2 trial
  The Lancet Haematology 2025 DOI: 10.1016/s2352-3026(24)00354-5
  +Save
• A Brief Report on Pre-Transfusion Testing in Patients Receiving the Anti-CD38 Monoclonal Antibody for Hematological Disorders in India
  Indian Journal of Hematology and Blood Transfusion 2024 DOI: 10.1007/s12288-024-01763-5
  +Save
• Melphalan-associated encephalopathy following autologous stem cell transplant: a transplanter�fs nightmare!
  BLOOD CELL THERAPY / The official journal of APBMT 2024 DOI: 10.31547/bct-2023-025
  +Save
• ABO-Mismatch Hematopoietic Stem Cell Transplantation with Pre-existing Red Cell Alloantibody Resembling a Case of Post-transplant Autoimmune Hemolytic Anemia
  Indian Journal of Hematology and Blood Transfusion 2024 DOI: 10.1007/s12288-024-01883-y
  +Save
• Bortezomib-based induction therapy followed by autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients: A single-center experience and review of Indian literature
  Indian Journal of Cancer 2023 DOI: 10.4103/ijc.ijc_78_22
  +Save
• Refractory Primary Mediastinal B-Cell Lymphoma: A Case Report of Conventional Chemotherapies, Immune Checkpoint Inhibitors, Polatuzumab Vedotin, Transplantation, and Post-Transplant Large Granular Lymphocytosis
  Indian Journal of Medical and Paediatric Oncology 2022 DOI: 10.1055/s-0042-1749412
  +Save
• Efficacy and Safety of Vodobatinib in Patients (pts) with Chronic Phase Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML): A Sub Group Analysis By Lines of Tyrosine Kinase Inhibitor (TKI) Therapy
  Blood 2022 DOI: 10.1182/blood-2022-166452
  +Save
• Hematopoietic Stem/Progenitor Cells and Engineering: HALF-TRUTH: GRAFT CRYOPRESERVATION DOES NOT IMPACT ENGRAFTMENT AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT (ALLO-HCT)-A SINGLE CENTER EXPERIENCE FROM INDIA
  Cytotherapy 2022 DOI: 10.1016/s1465-3249(22)00283-3
  +Save
• Primary Central Nervous System Lymphoma: Long-Term Treatment Outcomes and Cost-Analysis from a Retrospective Study of High-Dose Methotrexate Based Chemoimmunotherapy and Reduced Dose Radiation Therapy Approach
  Indian Journal of Hematology and Blood Transfusion 2022 DOI: 10.1007/s12288-021-01444-7
  +Save
• Relapsed Refractory Hodgkin Lymphoma and Brentuximab Vedotin-Bendamustine Combination Therapy as a Bridge to Transplantation: Real-World Evidence From a Middle-Income Setting and Literature Review
  Frontiers in Oncology 2022 DOI: 10.3389/fonc.2021.796270
  +Save